SCHEMBL17199353

SCHEMBL17199353

Cc1ccoc1C(=O)Nc1nn(Cc2ccc(CF)cc2)c2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FSCN1 Q16658 1/20 0.57
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GRM1 Q13255 6/20 0.40
GRM4 Q14833 4/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
PTGER4 P35408 5/20 0.39
CNR1 P21554 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30695043 0.89 FSCN1 (0.73) FSCN1KDM4EGAASMN1; SMN2GRM1
SCHEMBL17038990 0.89 FSCN1 (0.73) FSCN1KDM4EGAASMN1; SMN2GRM1
SCHEMBL18937505 0.86 FSCN1 (0.57) FSCN1GAASMN1; SMN2HDAC3HDAC1
SCHEMBL17199316 0.85 FSCN1 (0.54) FSCN1SMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL17199352 0.85 FSCN1 (0.52) FSCN1HDAC3HDAC1HDAC2HDAC10
SCHEMBL17199315 0.82 FSCN1 (0.55) FSCN1KDM4EGAASMN1; SMN2HDAC3
SCHEMBL17199381 0.81 FSCN1 (0.54) FSCN1KDM4EGRM1HDAC3HDAC1
SCHEMBL17199370 0.81 FSCN1 (0.51) FSCN1HDAC3HDAC1HDAC2HDAC10
SCHEMBL17199347 0.81 FSCN1 (0.60) FSCN1SMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL17199349 0.80 FSCN1 (0.50) FSCN1GRM1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170158692-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN CORNELL UNIVERSITY 2017-06-08 US disclosed
US-9573946-B2 Compounds and methods for inhibiting fascin NOVITA PHARMACEUTICALS, INC. (US) 2017-02-21 US disclosed
US-20150299191-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN CORNELL UNIVERSITY 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299191-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN FSCN1, MTPN, MYOF FSCN1 1/4885KDM4E 4674/4885GAA 630/4885
US-20170158692-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN FSCN1, MTPN, MYOF FSCN1 1/4885KDM4E 4674/4885GAA 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.